Publications by authors named "Paulo E Leaes"
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol
September 2021
Background: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness.
View Article and Find Full Text PDFObjective: To compare in-hospital outcomes in aortic surgery in our cardiac surgery unit, before and after foundation of our Center for Aortic Surgery (CTA).
Methods: Prospective cohort with non-concurrent control. Foundation of CTA required specialized training of surgical, anesthetic and intensive care unit teams, routine neurological monitoring, endovascular and hybrid facilities, training of the support personnel, improvement of the registry and adoption of specific protocols.
Article Synopsis
- - The study compared newer oxygenators designed to reduce immune response during cardiopulmonary bypass (CPB) in cardiac surgery with conventional oxygenators, focusing on their effects on lymphocyte activation and apoptosis.
- - Blood samples were taken from 20 patients (10 using each type of oxygenator) at various stages of surgery to assess lymphocyte surface markers and apoptosis through flow cytometry.
- - Results showed significant postoperative lymphopenia, increased lymphocyte activation, and decreased apoptosis in both groups, indicating that the reduced lymphocyte count after CPB is not primarily due to cell death.
Objective: To assess the effectiveness of metoprolol in preventing clinically detectable atrial fibrillation (AF) and flutter after coronary artery bypass graft (CABG) surgery.
Methods: An open, randomized study was carried out to treat 200 patients who had undergone isolated CABG surgery with extracorporeal circulation. The patients were randomized to either receive metoprolol orally or not to receive the medication in the postoperative period.